Company news
Duality Biotherapeutics, Inc. news in 2026
Duality Biotherapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Next Day Disclosure Return
November 6, 2026
Next Day Disclosure Return
November 5, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 5, 2026
Next Day Disclosure Return
November 3, 2026
Next Day Disclosure Return
November 2, 2026
Next Day Disclosure Return
October 30, 2026
Voluntary announcement - voluntary lock-up undertaking by directors and senior management
October 29, 2026
Voluntary announcement - update on share repurchases and proposed increase in shareholding by chairman of the board
October 28, 2026
Next Day Disclosure Return
October 28, 2026
Next Day Disclosure Return
October 27, 2026
Inside information - update on the dynasty-BREAST02 global Phase 3 clinical trial of trastuzumab pamirtecan
October 26, 2026
Next Day Disclosure Return
October 16, 2026
Next Day Disclosure Return
October 15, 2026
Next Day Disclosure Return
October 14, 2026
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
October 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
2026 Interim report
September 28, 2026
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
April 9, 2026
DualityBio (9606.HK) Announces 2025 Annual Results
March 24, 2026